Given that IL-34 seems to hinder macrophage phenotype and immunological response to Aβ challenge, peripheral blood blockade of IL-34 in patients suffering with AD may represent a potential therapeutic avenue by allowing for differentiation and development of adept macrophages more strongly suited to remove pathological Aβ. The gene discussed is IL34; the disease is Alzheimer disease.